


Box/Seq 1648

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/586,479	
	Filing Date	June 1, 2000	
	First Named Inventor	Schmidt, Alexander, et. al.	
	Group Art Unit	Unassigned	
	Examiner Name	Unassigned	
Total Number of Pages in This Submission	34	Attorney Docket Number	15280399100

MAR 14 2001

RECEIVED

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Response (Preliminary) <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Response to Notice to Comply with Sequence Disclosure Paper Sequence Listing Computer Readable Form copy of Sequence Listing Copy of Notice to Comply with Sequence Disclosure
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm and Individual name	Townsend and Townsend and Crew LLP Jeffrey J. King	Customer No. 20350 Reg No. 38,515
Signature		
Date	03/05/01	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:	
03/05/01	
Typed or printed name	Linda M. Povinelli
Signature	
Date	3/5/01

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SE 5007195 v1

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Box Sequence, Assistant Commissioner for Patents, Washington, D.C. 20231, on March 5, 2001


TOWNSEND and TOWNSEND and CREW LLP

By: 

PATENT

Attorney Docket No.: 15280-399100US

Client Reference No.: E-115-00/0



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Alexander C. Schmidt, et al.

Application No.: 09/586,479

Filed: June 1, 2000

For: ATTENUATED HUMAN-BOVINE
CHIMERIC PARAINFLUENZA VIRUS
(PIV) VACCINES

Examiner: S. Brown

Art Unit: 1648

**RESPONSE TO NOTICE TO COMPLY
WITH SEQUENCE DISCLOSURE**

Box Sequence
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the "Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" dated February 5, 2001, Applicants submit the enclosed Paper Sequence Listing to be made of record in the above-referenced application. Also enclosed is a computer readable form (CRF) copy of the Sequence Listing.

Pursuant to 37 CFR §1.821(f) and (g), it is believed that the content of the paper sequence listing and the computer readable sequence listing are the same. Further, the present submission of the Paper Sequence Listing and CRF Sequence Listing is not believed to constitute new matter.

RECEIVED
MAR 16 2001
TECH CENTER 1600/2900


BEST AVAILABLE COPY

Please charge (or credit) any fees associated with this response to the firm's
Deposit Account No. 20-1430.

If the Examiner believes a telephone conference would expedite prosecution of
this application, please telephone the undersigned at 206-467-9600.

Respectfully submitted,

Dated: March 5, 2001



Jeffrey J. King
Reg. No. 68,515

Customer No. 20350

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Phone (206) 467-9600
Fax (415) 576-0300
JJK:imp

SE 5006913 v1

101 AVAILABLE COPY



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Box Sequence, Assistant Commissioner for Patents, Washington, D.C. 20231, on March 5, 2001

TOWNSEND and TOWNSEND and CREW LLP

By: 

PATENT
Attorney Docket No.: 15280-399100US
Client Reference No.: E-115-00/0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Alexander C. Schmidt, et al.

Application No.: 09/586,479

Filed: June 1, 2000

For: ATTENUATED HUMAN-BOVINE
CHIMERIC PARAINFLUENZA VIRUS
(PIV) VACCINES

Examiner: S. Brown

Art Unit: 1648

*als
1.2.7
3/27/01*

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of the above-referenced application, please enter the following amendments and remarks.

IN THE SPECIFICATION:

Applicants submit the enclosed Sequence Listing to be made of record in the above-referenced application.

Please replace the paragraph beginning at page 21, line 8, with the following rewritten paragraph:

-- Figure 1 illustrates cloning of the N coding region of bovine PIV strains Ka or SF into HPIV3. In Fig. 1A-C, the BPIV3 N open reading frame (ORF) replaces its corresponding HPIV3 sequence in the full-length rJS antigenomic cDNA (Durbin et al., 1997a, *supra*). BPIV3 Ka and SF N genes were first amplified by RT-PCR using standard molecular

Ch